MeSH tree: C20.543.480.904
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).
May 5, 2026
0
6
Two new studies presented at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shed light on how hereditary angioedema (HAE)—a rare, potentially life-threatening disease ...
Nov 6, 2025
0
14
Many pregnant women experience allergies, asthma, or reactions to medications—conditions that can affect both mother and baby if not carefully managed. Yet new research presented at the 2025 American College of Allergy, Asthma ...
Nov 6, 2025
0
7
An analysis in the Journal of the American Geriatrics Society reveals that older inpatients admitted by physicians who prescribe higher amounts of first-generation antihistamines face an elevated risk of delirium while in ...
Oct 22, 2025
0
26
Exercise is good for the body and the mind. A good workout can leave you feeling energized, recharged and ready to take on the rest of the day.
Oct 8, 2025
0
13
HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of the diverse variants of HIV. Neutralizing antibodies are proteins produced by the immune system ...
Despite the glorious arrival of summer, there's definitely a sting in the season's tail—quite literally. Even in the UK, it's not just sunburn we need to watch out for. From nettles to jellyfish, summer brings a full cast ...
Jul 14, 2025
0
8
The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE).
Jun 21, 2025
0
19
A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and tolerability of three investigational HIV-1 trimer mRNA vaccines. The study vaccines were found to be generally ...
Apr 29, 2025
0
39
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, ...
Oct 24, 2024
0
42
